Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy in Mycobacterium avium complex pulmonary disease. // Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S2405579426000434?dgcid=rss_sd_all
Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy in Mycobacterium avium complex pulmonary disease. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. https://www.sciencedirect.com/science/article/pii/S2405579426000434?dgcid=rss_sd_all
“Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy in Mycobacterium avium complex pulmonary disease.” Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.
@article{article53031,
title = {Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy in Mycobacterium avium complex pulmonary disease},
journal = {Journal of Clinical Tuberculosis and Other Mycobacterial Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S2405579426000434?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...